AVBP

NASDAQ 已收盘

ArriVent BioPharma

11.26 USD
▲+0.36+3.30%
盘后 12.47 0.00%
2026-11-19
市值
$544.13M
市盈率
—
EPS
-3.67
股息率
—
52 周区间
10.33 – 35.83
成交量
906.60K
Beta
1.66
目标价
26.20
52W 低 10.3352W 高 35.83
价格走势

公司简介

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC...

关联新闻